Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone as adjuvant therapy for major depressive disorder
IRCT20090117001556N141Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lumateperone in major depressive disorder (MDD), sponsored by Tehran University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N141.